E
Evgenia Konstantakopoulou
Researcher at University College London
Publications - 29
Citations - 783
Evgenia Konstantakopoulou is an academic researcher from University College London. The author has contributed to research in topics: Glaucoma & Ocular hypertension. The author has an hindex of 13, co-authored 24 publications receiving 493 citations. Previous affiliations of Evgenia Konstantakopoulou include University of London & University of the West.
Papers
More filters
Journal ArticleDOI
Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial
Gus Gazzard,Gus Gazzard,Evgenia Konstantakopoulou,Evgenia Konstantakopoulou,David F. Garway-Heath,David F. Garway-Heath,Anurag Garg,Anurag Garg,Victoria Vickerstaff,Rachael Hunter,Gareth Ambler,Catey Bunce,Catey Bunce,Richard Wormald,Richard Wormald,Richard Wormald,Neil Nathwani,Keith Barton,Keith Barton,Gary S. Rubin,Marta Buszewicz,Rupert R A Bourne,David C Broadway,Amanda Davis,Hari Jayaram,Yuzhen Jiang,Sheng Lim,Joanna Liput,Timothy Manners,Stephen Morris,Nicholas G. Strouthidis,Sarah L Wilson,Haogang Zhu +32 more
TL;DR: Over 36 months, from an ophthalmology cost perspective, there was a 97% probability of selective laser trabeculoplasty as first treatment being more cost-effective than eye drops first at a willingness to pay of £20 000 per quality-adjusted life-year gained.
Journal ArticleDOI
Primary Selective Laser Trabeculoplasty for Open-Angle Glaucoma and Ocular Hypertension: Clinical Outcomes, Predictors of Success, and Safety from the Laser in Glaucoma and Ocular Hypertension Trial.
Anurag Garg,Anurag Garg,Victoria Vickerstaff,Neil Nathwani,David F. Garway-Heath,David F. Garway-Heath,Evgenia Konstantakopoulou,Evgenia Konstantakopoulou,Gareth Ambler,Catey Bunce,Richard Wormald,Richard Wormald,Richard Wormald,Keith Barton,Keith Barton,Gus Gazzard,Gus Gazzard,Rupert R A Bourne,David C Broadway,Marta Buszewicz,Amanda Davis,Rachael Hunter,Hari Jayaram,Yuzhen Jiang,Sheng Lim,Joanna Liput,Timothy Manners,Stephen Morris,Gary S. Rubin,Nicholas G. Strouthidis,Sarah L Wilson,Haogang Zhu +31 more
TL;DR: Primary SLT achieved comparable early absolute IOP-lowering in OHT versus OAG eyes, and total SLT power and 2-month IOP were predictors of drop-free disease-control at 36 months after single SLT.
Journal ArticleDOI
Laser in Glaucoma and Ocular Hypertension (LiGHT) Trial. A multicentre, randomised controlled trial: design and methodology
Gus Gazzard,Gus Gazzard,Evgenia Konstantakopoulou,Evgenia Konstantakopoulou,Evgenia Konstantakopoulou,David F. Garway-Heath,David F. Garway-Heath,Keith Barton,Richard Wormald,Richard Wormald,Stephen Morris,Rachael Hunter,Gary S. Rubin,Marta Buszewicz,Gareth Ambler,Catey Bunce,Catey Bunce,Catey Bunce +17 more
TL;DR: The LiGHT Trial is a multicentre, pragmatic, randomised clinical trial that will provide valuable data on the relative HRQL, clinical effectiveness and cost-effectiveness of SLT and topical IOP-lowering medication.
Journal ArticleDOI
Selective laser trabeculoplasty versus drops for newly diagnosed ocular hypertension and glaucoma: the LiGHT RCT.
Gus Gazzard,Gus Gazzard,Evgenia Konstantakopoulou,Evgenia Konstantakopoulou,David F. Garway-Heath,David F. Garway-Heath,Anurag Garg,Anurag Garg,Victoria Vickerstaff,Rachael Hunter,Gareth Ambler,Catey Bunce,Catey Bunce,Richard Wormald,Richard Wormald,Richard Wormald,Neil Nathwani,Keith Barton,Keith Barton,Gary S. Rubin,Stephen Morris,Marta Buszewicz +21 more
TL;DR: A 36-month pragmatic, unmasked, multicentre randomised controlled trial to compare health-related quality of life (HRQoL) in newly diagnosed, treatment-naive patients with OAG or OHT, treated with two treatment pathways: topical IOP-lowering medication from the outset or primary SLT followed by topical medications as required (Laser-1st).
Journal ArticleDOI
Cost Effectiveness of Treatments for Diabetic Retinopathy: A Systematic Literature Review
Nikolaos Maniadakis,Evgenia Konstantakopoulou,Evgenia Konstantakopoulou,Evgenia Konstantakopoulou +3 more
TL;DR: There is a pressing need for more advanced and standardised approaches to assessing the effectiveness and cost effectiveness of the emerging anti-VEGF pharmacotherapies for the treatment of DMO.